http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-1590661-A2
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59c6a921f33fe0adc58c2b6177184515 |
classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0356 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-05 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0306 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-28 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-705 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A01K67-027 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-47 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-705 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-02 |
filingDate | 2003-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_754292717eef62040954e3a1f4052837 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9336335618fdad4217561eea07e0e9d5 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e182e6e83fc9b9b5b56c039eb51f77bf |
publicationDate | 2005-11-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | EP-1590661-A2 |
titleOfInvention | Organic anion transport polypeptide related protein-4 (oatprp4) gene in tourette syndrome and related disorders |
abstract | The present invention identifies that modification, i.e., disruption, of the OATPRP-4 gene and/or its protein product(s) correlates with the predisposition for Tourette syndrome (TS) and/or related disorders. Provided herein, therefore, is a research model for screening compounds and/or small molecules for the ability to reduce, ameliorate or modulate TS and/or related disorders by administering the compound or small molecule to a transgenic animal having a disrupted OATPRP-4 gene and/or protein product(s) of the gene and then measuring or observing if the compound or small molecule reduces, ameliorates or modulates signs and/or symptoms of TS and/or related disorders. Additionally, a research model is provided using an human or animal cell line having a disrupted OATPRP-4 gene and/or protein product(s) of the gene, as well as methods for diagnosing and treating animals or humans having a predisposition for or manifesting symptoms of TS and/or related disorders. Finally, the present invention provides a transgenic animal model, an animal cell line, an animal primary cell culture line of a transgenic animal, a human cell line, and a human primary cell culture line, all of which have a disruption of a OATPRP-4 gene or a disruption of a homologue of the OATPRP-4 gene therein. |
priorityDate | 2002-11-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 95.